Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 07/16/20
End: 02/14/24
Due: 02/14/25
Phase: N/A
Priority: Normal
Start: 12/01/17
End: 03/31/25
Due: 03/31/26
Phase: N/A
Priority: Normal
Start: 09/30/15
End: 11/30/17
Due: 11/30/18
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor | NCT04416516 | Ascend Biopharmaceuticals Ltd | user2@example.com | None | 2020-07-16 | 2024-02-14 | 2025-02-14 | - | - | 2025-07-14 |
| Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS) | NCT03208296 | Ascend Biopharmaceuticals Ltd | user2@example.com | None | 2017-12-01 | 2025-03-31 | 2026-03-31 | - | - | 2025-07-14 |
| A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma | NCT02550678 | Ascend Biopharmaceuticals Ltd | user2@example.com | None | 2015-09-30 | 2017-11-30 | 2018-11-30 | - | - | 2025-07-14 |